Meeting
2021 ASCO Annual Meeting
Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.
Authors
Binod Dhakal
Medical College of Wisconsin, Milwaukee, WI
Binod Dhakal , Shruti Sharma , Svetlana Shchegrova , Minu Maninder , Meenakshi Malhotra , Himanshu Sethi , Bernhard Zimmermann , Paul R. Billings , Alexey Aleshin , Parameswaran Hari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8029)
DOI
10.1200/JCO.2021.39.15_suppl.8029
Abstract #
8029
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Patient-specific tumor-informed circulating tumor DNA (ctDNA) assay to predict cancer recurrence in patients with resected pancreatic cancer.
First Author: Xiuchao Wang
Poster
2022 ASCO Annual Meeting
Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.
First Author: Rong Yin
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.
First Author: Noelia Tarazona
Poster
2024 ASCO Annual Meeting
Utilization of tumor-informed circulating tumor DNA in detecting minimal residual disease and guiding adjuvant therapy in liver cancer.
First Author: De-Zhen Guo